Zai Lab (1ZL) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1ZL Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Zai

Lab

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1ZL Stock 12 Month Forecast

Average Price Target

€28.38

▲(47.79% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Zai Lab in the last 3 months. The average price target is €28.38 with a high forecast of €38.54 and a low forecast of €18.92. The average price target represents a 47.79% change from the last price of €19.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","39":"€39","18.75":"€18.75","25.5":"€25.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38.53537556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.376049276000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.917366184,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€18.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,18.75,25.5,32.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17,18.65656735076923,20.313134701538463,21.969702052307692,23.626269403076922,25.282836753846155,26.939404104615384,28.595971455384614,30.252538806153844,31.909106156923077,33.56567350769231,35.22224085846153,36.87880820923077,{"y":38.53537556,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17,17.875080713538463,18.750161427076925,19.625242140615384,20.500322854153847,21.37540356769231,22.250484281230772,23.125564994769235,24.000645708307694,24.875726421846156,25.75080713538462,26.625887848923078,27.500968562461544,{"y":28.376049276000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17,17.14748970646154,17.294979412923077,17.442469119384615,17.589958825846153,17.737448532307692,17.88493823876923,18.03242794523077,18.179917651692307,18.327407358153845,18.474897064615384,18.622386771076922,18.76987647753846,{"y":18.917366184,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€38.54

Average Price Target€28.38

Lowest Price Target€18.92

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

€28.03→€23.65

Buy

23.16%

Upside

Reiterated

05/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (NYSE: HCA) and Zai Lab (NASDAQ: ZLAB)

David Li

Bank of America Securities

€19.09→€18.92

Hold

-1.47%

Downside

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Zai Lab (NASDAQ: ZLAB) and NanoViricides (NYSE MKT: NNVC)

Yigal Nochomovitz

Citi

€41.16→€38.54

Buy

100.71%

Upside

Reiterated

05/08/26

Citi Sticks to Its Buy Rating for Zai Lab (ZLAB)

Li Watsek

Cantor Fitzgerald

€32.4

Buy

68.77%

Upside

Reiterated

04/29/26

Zai Lab (ZLAB) Gets a Buy from Cantor Fitzgerald

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

€37.58→€32.4

Buy

68.73%

Upside

Reiterated

01/15/26

Zai Lab (ZLAB) Receives a Buy from Goldman Sachs

Michael Yee

UBS

€30.65

Buy

59.65%

Upside

Initiated

01/07/26

Zai Lab initiated with a Buy at UBSZai Lab initiated with a Buy at UBS

Jonathan Chang

Leerink Partners

€64.81

Buy

237.55%

Upside

Reiterated

10/21/25

Leerink Partners Sticks to Their Buy Rating for Zai Lab (ZLAB)

Jack Lin

Morgan Stanley

€45.54→€42.04

Buy

118.95%

Upside

Reiterated

09/21/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Zai Lab (NASDAQ: ZLAB)

Kelly Shi

Jefferies

€45.54

Buy

137.20%

Upside

Initiated

08/24/25

Jefferies assumes Zai Lab (ZLAB) at BuyJefferies analyst Kelly Shi assumes coverage on Zai Lab (NASDAQ: ZLAB) with a Buy rating and a price target of $52.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

€28.03→€23.65

Buy

23.16%

Upside

Reiterated

05/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (NYSE: HCA) and Zai Lab (NASDAQ: ZLAB)

David Li

Bank of America Securities

€19.09→€18.92

Hold

-1.47%

Downside

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Zai Lab (NASDAQ: ZLAB) and NanoViricides (NYSE MKT: NNVC)

Yigal Nochomovitz

Citi

€41.16→€38.54

Buy

100.71%

Upside

Reiterated

05/08/26

Citi Sticks to Its Buy Rating for Zai Lab (ZLAB)

Li Watsek

Cantor Fitzgerald

€32.4

Buy

68.77%

Upside

Reiterated

04/29/26

Zai Lab (ZLAB) Gets a Buy from Cantor Fitzgerald

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

€37.58→€32.4

Buy

68.73%

Upside

Reiterated

01/15/26

Zai Lab (ZLAB) Receives a Buy from Goldman Sachs

Michael Yee

UBS

€30.65

Buy

59.65%

Upside

Initiated

01/07/26

Zai Lab initiated with a Buy at UBSZai Lab initiated with a Buy at UBS

Jonathan Chang

Leerink Partners

€64.81

Buy

237.55%

Upside

Reiterated

10/21/25

Leerink Partners Sticks to Their Buy Rating for Zai Lab (ZLAB)

Jack Lin

Morgan Stanley

€45.54→€42.04

Buy

118.95%

Upside

Reiterated

09/21/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Zai Lab (NASDAQ: ZLAB)

Kelly Shi

Jefferies

€45.54

Buy

137.20%

Upside

Initiated

08/24/25

Jefferies assumes Zai Lab (ZLAB) at BuyJefferies analyst Kelly Shi assumes coverage on Zai Lab (NASDAQ: ZLAB) with a Buy rating and a price target of $52.00.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KURAKura Oncology

CSTLCastle Biosciences

VKTXViking Therapeutics

ATECAlphatec Holdings

TRVITrevi Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zai Lab

3 Months

Anupam RamaJ.P. Morgan

Success Rate

7/15 ratings generated profit

Average Return

+0.34%

Copying Anupam Rama's trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +0.34% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

9/15 ratings generated profit

Average Return

+6.90%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +6.90% per trade.

2 Years

Anupam RamaJ.P. Morgan

Success Rate

6/15 ratings generated profit

Average Return

-10.78%

Copying Anupam Rama's trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -10.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1ZL Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1ZL has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1ZL average Analyst price target in the past 3 months is 28.38.

Each month's total comprises the sum of three months' worth of ratings.

1ZL Financial Forecast

1ZL Earnings Forecast

Next quarter’s earnings estimate for 1ZL is -€0.58 with a range of -€0.86 to -€0.46. The previous quarter’s EPS was -€0.40. 1ZL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 1ZL has Performed in-line its overall industry.

1ZL Sales Forecast

Next quarter’s sales forecast for 1ZL is €90.90M with a range of €89.06M to €94.95M. The previous quarter’s sales results were €87.32M. 1ZL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 1ZL has Performed in-line its overall industry.

1ZL Stock Forecast FAQ

What is DE:1ZL’s average 12-month price target, according to analysts?

Based on analyst ratings, Zai Lab Ltd’s 12-month average price target is 28.38.

What is DE:1ZL’s upside potential, based on the analysts’ average price target?

Zai Lab Ltd has 47.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Zai Lab Ltd a Buy, Sell or Hold?

Zai Lab Ltd has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Zai Lab Ltd’s share price target?

The average share price target for Zai Lab Ltd is 28.38. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €38.54 ,and the lowest forecast is €18.92. The average share price target represents 47.79% Increase from the current price of €19.2.

What do analysts say about Zai Lab Ltd?

Zai Lab Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Zai Lab Ltd?

To buy shares of DE:1ZL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Zai Lab (1ZL) Stock Forecast & Price Target

1ZL Analyst Ratings

1ZL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zai Lab

1ZL Analyst Recommendation Trends

1ZL Financial Forecast

1ZL Earnings Forecast

1ZL Sales Forecast

1ZL Stock Forecast FAQ

Detailed List of Analyst Forecasts